ISRCTN17639209已完成Unknown
The digital Hope Programme for adults with polycystic ovary syndrome (Hope PCOS): a mixed methods feasibility randomised controlled trial
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age 18+ years
- •2. UK based
- •3. Self report that diagnosis of PCOS has been confirmed by participant's general practitioner and/or a hospital specialist.
- •4. Capacity to give informed consent
- •5. Ability to communicate in English, to participate in the intervention and complete outcome measures
- •6. Internet connection and internet-enabled device.
排除标准
- •1. Age less than 18 years
- •2. Non-UK based
- •3. No diagnosis of PCOS, or diagnosis has not been confirmed by participant's general practitioner and/or a hospital specialist.
研究者
相似试验
招募中
3 期
A Phase 3 Study with Open-Label Extension of BLU-5937 to determine Efficacy and Safety in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)CTRI/2023/06/054278Bellus Health, Inc.
招募中
3 期
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1)RCCNL-OMON56306Bellus Health, Inc.24
进行中（未招募）
1 期
A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Unexplained Chronic CoughEUCTR2022-000223-20-NLBellus Health, Inc.675
招募中
1 期
A Phase 3, 24-Week, Randomized, Efficacy and Safety Study with Openlabel Extension of BLU-5937 in Adult Participants with Refractory or Unexplained Chronic Cough (CALM-2)Refractory Chronic Cough, Including Unexplained Chronic CoughMedDRA version: 21.0Level: LLTClassification code: 10080782Term: Refractory chronic cough Class: 10038738MedDRA version: 21.1Level: LLTClassification code: 10066656Term: Chronic cough Class: 10038738CTIS2024-513462-19-00Bellus Health Inc.771
尚未招募
3 期
A Phase 3 study to determine Efficacy and Safety Study of BLU-5937 in Adult Participants with Refractory Chronic Cough.CTRI/2023/11/060301Bellus Health, Inc.